Search

Your search keyword '"Nakashima, Ichiro"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Nakashima, Ichiro" Remove constraint Author: "Nakashima, Ichiro" Journal neurology Remove constraint Journal: neurology
37 results on '"Nakashima, Ichiro"'

Search Results

1. Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD

2. Efficacy and Safety of Ravulizumab in Adults With Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+ NMOSD): Interim Analysis From the Ongoing Phase 3 CHAMPION-NMOSD Trial (S32.003)

4. Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension

7. Indirect Comparison Analysis of FDA-Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (P15-1.007)

9. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder

10. Long-term efficacy and safety of eculizumab monotherapy in AQP4+ neuromyelitis optica spectrum disorder (1578)

11. Area postrema syndrome

12. Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (1780)

13. Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (1765)

14. Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494)

15. Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299)

16. Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788)

17. Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003)

18. Hypoxia-like tissue injury and glial response contribute to Balo concentric lesion development

20. Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder

22. New Acute Severity Scale for Neuromyelitis Optica Relapses (P5.249)

23. A Multicentric Cross-sectional Study of the Usefulness of Cerebrospinal Fluid-Glial Fibrillary Acidic Protein (CSF-GFAP) in the Diagnosis and Prognosis of Inflammatory Demyelinating Diseases (P4.133)

24. Neuromyelitis Optica Spectrum with Autoantibodies Against Myelin-Oligodendrocyte Glycoprotein Have Distinct Clinical Features and Prognosis from Seronegative Patients (S63.006)

25. Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnostic Criteria for NMO Spectrum Disorders (P2.266)

26. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

27. Aquaporin-4 antibody–positive cases beyond current diagnostic criteria for NMO spectrum disorders

28. Brainstem Manifestations in Neuromyelitis Optica (P02.144)

29. The Importance of Aquaporin-4 Antibody Assays in Patients beyond the Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (P02.156)

33. Author response.

36. Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.

37. Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody.

Catalog

Books, media, physical & digital resources